This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Epizyme マネジメント

マネジメント基準チェック /24

主要情報

Grant Bogle

最高経営責任者

US$3.0m

報酬総額

CEO給与比率	9.9%
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	10.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Epizyme の収益と比較して、Grant Bogle の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2022	n/a	n/a	-US$208m
Mar 31 2022	n/a	n/a	-US$236m
Dec 31 2021	US$3m	US$299k	-US$251m
Sep 30 2021	n/a	n/a	-US$267m
Jun 30 2021	n/a	n/a	-US$257m
Mar 31 2021	n/a	n/a	-US$251m
Dec 31 2020	US$196k	n/a	-US$232m
Sep 30 2020	n/a	n/a	-US$222m
Jun 30 2020	n/a	n/a	-US$202m
Mar 31 2020	n/a	n/a	-US$192m
Dec 31 2019	US$309k	n/a	-US$173m

報酬と市場: Grant's total compensation ($USD3.01M) is above average for companies of similar size in the German market ($USD815.36K).

報酬と収益: Grant's compensation has increased whilst the company is unprofitable.

CEO（最高経営責任者

Grant Bogle (64 yo)

less than a year

在職期間

US$3,011,807

報酬

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Grant Bogle	President	less than a year	US$3.01m	データなし
Jeffery Kutok	Chief Scientific Officer	2.3yrs	US$2.86m	0.0080% $ 19.4k
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	データなし	データなし
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	データなし	データなし
Jerald Korn	Chief Operating Officer	less than a year	データなし	データなし
Joseph Beaulieu	Senior VP	4.1yrs	データなし	0.0058% $ 13.9k
Craig West	Vice President of Investor Relations	no data	データなし	データなし
John Weidenbruch	Senior VP	no data	データなし	データなし
Tanja Weber	Chief Business Officer	3.6yrs	データなし	データなし
Mark De Rosch	Chief Regulatory Officer	2.8yrs	データなし	データなし
Rebecca Mehrwerth	Senior VP & Head of Commercial	less than a year	データなし	データなし
Christoph Diefenbach	Laboratory Manager of Research & Development	no data	データなし	データなし

2.3yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: EPE's management team is considered experienced (2.3 years average tenure).

取締役

名称	ポジション	在職期間	報酬	所有権
Grant Bogle	President	2.9yrs	US$3.01m	データなし
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	データなし	データなし
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	データなし	データなし
George Daley	Member of the Scientific Advisory Board	no data	データなし	データなし
David Mott	Independent Chairman	12.7yrs	US$370.00k	0.19% $ 462.3k
Carl Goldfischer	Independent Director	12.9yrs	US$350.00k	0.0030% $ 7.2k
Christopher Walsh	Member of the Scientific Advisory Board	no data	データなし	データなし
Kenneth Bate	Independent Director	7.7yrs	US$330.94k	0% $ 0
Bruce Chabner	Member of the Scientific Advisory Board	no data	データなし	データなし
Ronald Evans	Member of the Scientific Advisory Board	no data	データなし	データなし
Joel Huff	Member of the Scientific Advisory Board	no data	データなし	データなし
Steven Henikoff	Member of the Scientific Advisory Board	no data	データなし	データなし

10.2yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: EPE's board of directors are seasoned and experienced ( 10.2 years average tenure).

This company listing is no longer active

Epizyme マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Independent Chairman recently bought €424k worth of stock

Independent Director recently bought €51k worth of stock

Epizyme, Inc. Announces Executive Promotions

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.63 loss in 2Q 2021)

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

First quarter 2022 earnings released: US$0.39 loss per share (vs US$0.69 loss in 1Q 2021)

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Director Kevin Conroy has joined 4th company board

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought €424k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Revenue beats expectations

New 90-day low: €8.50

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: €9.30

Independent Director recently bought €51k worth of stock

New 90-day low: €9.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue misses expectations

Epizyme, Inc. Announces Executive Promotions

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: €10.00

First half earnings released

New 90-day low - €11.60

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24